Acadian Asset Management’s Karyopharm Therapeutics KPTI Stock Holding History

Acadian Asset Management’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.38M	Buy	248,957 +245,231	+6,582%	+$1.87M	﹤0.01%	1069
2025 Q4	$27K	Buy	+3,726	New	+$22.8K	﹤0.01%	1872
2025 Q1	–	Sell	-22,856	Closed	-$230K	–	1720
2024 Q4	$230K	Sell	22,856 -1,711	-7%	-$20.7K	﹤0.01%	1239
2024 Q3	$304K	Buy	24,567 +11,622	+90%	+$144K	﹤0.01%	1225
2024 Q2	$167K	Buy	+12,945	New	+$214K	﹤0.01%	1460
2024 Q1	–	Sell	-18,337	Closed	-$237K	–	1683
2023 Q4	$237K	Buy	+18,337	New	+$247K	﹤0.01%	1206
2023 Q3	–	Sell	-6,596	Closed	-$177K	–	1747
2023 Q2	$177K	Buy	+6,596	New	+$284K	﹤0.01%	1296
2023 Q1	–	Sell	-56,383	Closed	-$2.87M	–	1854
2022 Q4	$2.87M	Sell	56,383 -322	-0.6%	-$22.3K	0.01%	586
2022 Q3	$4.64M	Buy	56,705 +44,352	+359%	+$3.31M	0.03%	417
2022 Q2	$836K	Sell	12,353 -20,908	-63%	-$1.92M	﹤0.01%	852
2022 Q1	$3.67M	Buy	+33,261	New	+$4.15M	0.02%	526
2019 Q2	–	Sell	-3,796	Closed	-$333K	–	1935
2019 Q1	$333K	Buy	+3,796	New	+$421K	﹤0.01%	1220
2017 Q2	–	Sell	-272	Closed	-$52K	–	1515
2017 Q1	$52K	Buy	+272	New	+$43.7K	﹤0.01%	1230

Other funds holding KPTI

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Acadian Asset Management's KPTI Position: Q1 2026 in Review

Acadian Asset Management increased its Karyopharm Therapeutics (KPTI) stake by 6,582% in Q1 2026, buying an estimated $1.87M and bringing the position to 248,957 shares worth $1.38M. The position accounts for ﹤0.01% of the portfolio, ranked #1069.

Acadian Asset Management first reported a position in KPTI in Q1 2017 and has held it in 13 quarters since. The position peaked at $4.64M in Q3 2022. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

Acadian Asset Management held 248,957 shares of Karyopharm Therapeutics worth $1.38M as of Q1 2026.
Acadian Asset Management bought 245,231 Karyopharm Therapeutics shares in Q1 2026, an estimated $1.87M.
Karyopharm Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q1 2026, its #1069 holding.
Acadian Asset Management first reported a position in Karyopharm Therapeutics in Q1 2017 and has held it in 13 quarters since.
Acadian Asset Management's Karyopharm Therapeutics position peaked at $4.64M in Q3 2022.
77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.